Shengnuo Pharmaceutical-B (02257) announced interim results with profit attributable to shareholders of US$91,000, turning a year-on-year loss into profit

According to the Zhitong Finance App, Shengnuo Pharmaceutical-B (02257) announced results for the six months ended June 30, 2026. The group obtained additional revenue of 140,000 US dollars during the period, an increase of 12.9% over the previous year; profit attributable to the company owners was 91,000 US dollars, which turned a year-on-year loss into a profit; basic profit per share was 0.09 cents.